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The COVID-19 outbreak has impacted all aspects of life across the globe. Can you shed some light on the personal impact it has had on your lab and institution? What are you (or your institution) doing to support lab members and colleagues whose work has been disrupted during this time? {#sec1.1}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Deepak Srivastava (D.S.):** At Gladstone, we have suspended the majority of research operations, with the exception of research related to the virus. Although we are able to continue some work, such as data analysis and manuscript and grant preparation, the inability to perform wet lab experiments is unquestionably delaying discovery.

My laboratory has halted the majority of our experimental work. However, we are continuing lab meetings and journal clubs, and are holding virtual social gatherings, to ensure that people stay engaged. I am doing this for all of Gladstone also, holding town halls and weekly gatherings for faculty and ensuring frequent and transparent communication from me as President.

As Gladstone begins to formalize our reopening plans, we are surveying our community to ensure that we take all of their concerns into account. When shelter-in-place orders are lifted, we plan to resume research in stages, limiting occupancy in the building so that researchers can practice physical distancing while they are at work and providing masks to help prevent viral spread.

As President of the International Society for Stem Cell Research (ISSCR), I can say we are finding ways to support the entire stem cell community worldwide. To this end, we have converted our 2020 annual meeting (from June 24^th^ to 27^th^) to a virtual meeting and are excited to present a full program in a way that will allow scientists all over the world to attend at a low cost. We hope this format will reach more people than ever before.

**Fiona M. Watt (F.W.):** It has emphasized the importance of thinking through the impact from multiple perspectives. Before the lab was shut down, we discussed which key experiments had to be completed and who would carry them out if someone were to be taken ill. People with underlying health conditions or a long journey to work on crowded public transport opted to stay away before the official lockdown, but equally, some people have been going to work throughout---to take care of mice and top up liquid nitrogen tanks, for example.

We have managed to keep up our weekly group meetings and one-to-one discussions. We have continued our international seminar series (saving quite a lot of money on hotel and dinner bills), our informal "stem cells @ lunch" series, and the Centre for Stem Cells and Regenerative Medicine's journal club. Our superb public engagement officer has come up with many creative ways to keep lab members and members of the public engaged, entertained, and informed---she has even helped me to set up a Twitter account. At the moment she is interviewing lab members about their personal experiences of lockdown---everyone is asked to rate their lockdown on a scale of one to ten. I rated mine 9/10, but I am well aware that the situation has been incredibly difficult for many scientists---being in a different country from family, for example, or being alone in a tiny apartment with no balcony. Our lab community has always been supportive and there are virtual lab get-togethers for coffee or beers.

Now we are planning for a phased reopening of the lab. We are having a lot of discussions---how can we maintain social distancing? Who needs to get into the lab most urgently? There is a lot of trust and we have been clear from the outset that no one should be forced to come back early if they have good reasons to return last. Of course, we need to make our local plans in the context of the university position---one of the issues at the moment is whether researchers funded on grants can be furloughed.

**George Q. Daley (G.Q.D.):** By early March it was clear that COVID had become a pandemic disease. Fatality was highest among the elderly while young people were relatively resilient. Out of concern for the safety of *all* members of our community, we largely shuttered our labs to reduce the inevitable mixing that happens among scientific colleagues of different ages, but we allowed a few individuals to maintain liquid nitrogen tanks and animal strains or reagents that were deemed irreplaceable. Labs doing COVID-related research remained active, as long as the research was addressing immediate issues---those likely to impact patients within the next year---with a minimum number of scientists, and all wearing masks and practicing physical distancing. For the rest, we encouraged active engagement in online group meetings and journal clubs, and we strongly suggested this would be a good time to invest in writing grants and papers. We increased the number of Zoom licenses and our IT bandwidth to accommodate an enormous transition to online work.

The urgency of this crisis has shifted the focus of many research programs to tackle COVID-19-related problems. Do you have any insights about how to successfully pivot research activities, funding, and resources to adapt to these shifted priorities? {#sec1.2}
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**F.W.:** I am currently on secondment as Executive Chair of the Medical Research Council, one of the major biomedical research funders in the UK. It has been exhilarating to help run rapid calls for funding to tackle COVID-19---including grants for vaccine development to clinical trials of repurposed drugs. But in addition to new money for research, it is very impressive to see how quickly the community responded using their existing grants and building on experience gained from the SARS, MERS, Ebola, and Zika crises.

**G.Q.D.:** Across Harvard Medical School (HMS) we have a remarkable number of clinicians and scientists with expertise relevant to SARS-CoV-2, and many indeed pivoted their focus from current activities to study the virus or the clinical response. Fortunately, many of our investigators have discretionary sources of funding to allow speculative and creative work---or in this case, to change their focus. Some funders also expressed support for redirecting efforts toward the current crisis, which was a generous and deeply humanitarian decision. HMS also received a large philanthropic donation from the Evergrande Group and its Chairman Hui Ya Kan, a Chinese philanthropist whose previous support had established the Evergrande Center for Immunologic Disease at HMS and Brigham and Women's Hospital. This gift allowed us to support COVID-related projects and to establish a robust community of collaborators, regionally and internationally.

**D.S.:** Globally, a survey done by the ISSCR indicates that nearly 25% of stem cell scientists have pivoted some of their work to address COVID-19.

Gladstone has a strong history of responding to emerging viruses and has contributed to important discoveries related to HIV, Ebola, and Zika. As such, it was natural that our scientists dove into investigating SARS-CoV-2. Our virologists are designing new CRISPR-based diagnostic tests that can be done in-home, discovering mechanisms of viral entry and replication, and developing novel vaccine approaches building on our experiences with HIV.

In addition, our other scientists looked for ways their previous work might be relevant to understanding this novel virus. For example, as we have learned that COVID-19 patients experience cardiac and neurological symptoms, in addition to the effects in the lungs, Gladstone researchers who work in those areas found ways to contribute. As a hub of both stem cell research and virology, we have a unique opportunity to investigate how the virus infects various human stem cell-derived tissues, ranging from lung and brain organoids to human cardiomyocytes, and we can use these systems to screen small-molecule libraries to find candidate therapies. Computational approaches to understand genetic susceptibility and drug design have also been critical.

Funding COVID-19 work immediately has been a challenge and has required a focus on philanthropy and commercial partnerships. Fortunately, we have inspired new donors to support this work and had pro bono assistance from companies interested in this space, ranging from Bain Consulting to Amazon. Most prominently, the Roddenberry Foundation, established to honor Gene Roddenberry's vision of science helping humanity as displayed in Star Trek, has committed \$1 million to COVID-19 research. This is in addition to their support of the Roddenberry Stem Cell Center at Gladstone, which is also leveraging stem cell approaches to tackle the virus.

Are there organizational challenges or regulatory hurdles that have hindered your efforts? Do you have ideas for how to overcome them? {#sec1.3}
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**D.S.:** Gladstone has had a biosafety level 3 (BSL-3) facility for HIV work but we needed to develop a different BSL-3 space for COVID-19 research, as it is an air-borne rather than blood-borne pathogen. We identified space in the animal facility to convert for this purpose so we could use tissue culture for discovery work and develop animal models for preclinical trials. The BSL-3 facility required structural updates and many regulatory approvals before research with live virus could begin. We also needed to purchase dedicated equipment and secure PPE for the researchers who planned to use the facility. It has been a challenge to get this lab up and running, requiring tremendous effort from staff members and targeted fundraising. However, we have done so and the BSL-3 facility will open by the end of May. It will be a hub for scientists throughout the Bay Area while keeping all our scientists safe in the process.

**F.W.:** I am pleased to say that the UK government has been very receptive to advice from scientists, and the relevant regulators have moved very quickly indeed.

Because SARS-CoV-2 is a novel coronavirus, the pace of research and new insights is moving at an exceptionally fast rate. Can you share some insights on how to manage projects that need to come together and move forward quickly while adapting to a daily flow of new information? {#sec1.4}
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**G.Q.D.:** In early February, we began convening experts across HMS in virology, immunology, and a multitude of disciplines to confront the virus. We ultimately included clinicians and scientists from other institutions, and in a meeting held on March 2 (the date of the first reported case of COVID-19 in Massachusetts) we launched the Massachusetts Consortium on Pathogen Readiness (<https://massCPR.hms.harvard.edu>). Now over 500 scientists from our community are organized into six different working groups: diagnostics, epidemiology, therapeutics, vaccines, pathogenesis, and clinical management and outcomes research. Weekly Zoom meetings, some attended by more than 100 investigators, feature 5 or 6 lightning talks of no more than 5 min each, followed by questions and discussions. These catalyze rapid communication and spawn collaboration. We then hold weekly public webinars on topics like viral and sero-diagnostics, pathology, and clinical management, and thousands have been watching.

**D.S.:** Things are indeed moving at an unprecedented pace. It has taken dedicated project management to move at the speed we need, and we have frequent team meetings and journal clubs to keep up with new discoveries.

For one project involving development of a new point-of-care CRISPR-based diagnostic test, Bain Consulting has committed a pro bono team to help coordinate all the steps necessary to compress the timeframe for development from 18 months to 4--5 months. This will allow us to make an impact with a novel diagnostic by the fall, so that schools, workplaces, and other organizations can open with greater safety.

This crisis has shown the power of global collaboration. What changes have you made in your approaches to collaboration as a result of these circumstances? {#sec1.5}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

**G.Q.D.:** Our webinars and various case management discussions have included presentations by international colleagues from China and Italy. In some of the earliest video conferences, we learned valuable information about the nature of the COVID disease and its pathology, which gave our clinicians valuable insights into how best to care for our patients. Sharing expertise is essential for an optimal global response. A pandemic disease requires a pandemic flow of knowledge and information.

**D.S.:** Gladstone is an extremely collaborative environment, so it has been an extension of our usual approach to find areas where we can work together to answer important questions related to this virus. Our scientists have been working with groups across the country and world to accelerate discovery; this was reflected in a recent publication in *Nature* reporting the "roadmap" of all the human proteins that interact with the SARS-CoV-2 proteins. By collaborating with scientists at the Pasteur Institute and many others, we have found candidate drugs that disrupt these protein interactions and stop viral replication.

This pandemic coincided with a decision we made as an institution to pivot the focus of the Gladstone Institute of Virology and Immunology. Given the expansion of the two fields, we decided to create two new and distinct institutes, one focused on virology and a second on genomic immunology. The Institute of Virology will be led by Melanie Ott, who has experience investigating HIV and Zika, among other viruses, and who is spearheading our effort to open an air-borne pathogen BSL-3. The Gladstone-UCSF Institute of Genomic Immunology will be led by Alex Marson, whose work on genetically engineering T cells has tremendous potential to change the way we understand and treat many human diseases through manipulation of the immune system.

We have also leveraged the ISSCR to develop COVID-19 Stem Cell Networking calls to share unpublished data and approaches to use stem cell biology in the fight against the global pandemic. This interaction has created synergy and momentum, and we will have a dedicated session on the ISSCR's response to COVID-19 at our annual meeting in June.

The response to the pandemic has also highlighted the power of open science. Can you share your thoughts on how to best share data and resources in these circumstances? How has the constant stream of information challenged your ability to access and assess the reliability of open data? {#sec1.6}
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**G.Q.D.:** Science is by its nature competitive, but the common threat of COVID disease has evinced unprecedented levels of selfless collaboration, cooperation, and communication. It's been inspiring to witness so much open exchange and willingness to share unpublished data, all aimed at accelerating learning and discovery for everyone's benefit.

On the flip side, we've also witnessed the challenges of determining optimal clinical treatments from observation and anecdote alone. Some early experience in China and *in vitro* data suggested that hydroxychloroquine might be effective against SARS-CoV-2. Even our president championed its use. But randomized, controlled trials have now suggested that the risks outweigh the benefits, since patients treated with the drugs have suffered abnormal heart rhythms and some died. Past studies had shown hydroxychloroquine was active *in vitro* against HIV, flu, and chikungunya, but clinical studies found no benefit in HIV and flu and worse outcomes for chikungunya. The lesson we learned as a medical community is that even in the throes of a pandemic, we must be cautious about extrapolating laboratory research to the clinical setting. There is no substitute for rigorous clinical trial design to teach us which treatments work in patients and which don't.

**F.W.:** I have long been committed to publishing preprints---I have been on the Advisory Board of bioRxiv since 2013 and medRxiv since 2019. The current pandemic has shown how valuable these are for rapid dissemination of information. However, bioRxiv and medRxiv have also been clear that preprints describing work that has the potential to do harm, such as promoting unproven treatments, cannot be posted. The preprint servers have had to grow up fast.

**D.S.:** Open science is important, and in the face of a pandemic, there is tremendous pressure to move quickly, as discoveries could save lives. We are publishing our findings in open access journals immediately and sharing data even before that. That said, the flood of information has reinforced the value of peer review, as it has been challenging to wade through spurious reports to identify the most meaningful findings.

Is there anything different that you're doing with your approach to publishing COVID-19 research? How do you see the role of preprints in this publishing landscape? {#sec1.7}
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**G.Q.D.:** It's inspiring to see the energy with which biomedical scientists worldwide have redirected their focus on COVID-19 disease and how quickly they have mobilized to publicize their results for the common good. There has been an unprecedented uptick in submissions to all the major journals and to the preprint services medRxiv and bioRxiv. While there is real value to the rapid dissemination of ideas, there is a wide range of quality in what's being reported. I read the preprint papers from the perspective of a skeptical reviewer, not a critical consumer, because the data have often not been subject to even the most cursory peer review. I take data presented on these presubmission services with 10 molar sodium chloride. Some of the conclusions stimulate ideas and the best influence my current thinking, but I am a huge advocate for the rigor of peer review---imperfect as it is---for enhancing the quality of published literature.

**D.S.:** Under normal circumstances, scientists may choose to deposit a preprint of their work in a public archive for a number of reasons---to share their findings, collect input from colleagues, or position themselves early on as players in a field.

During this pandemic, depositing to bioRxiv or medRxiv has taken on new urgency, as a means for scientists to quickly communicate their findings and speed up discoveries that could lead to treatments or prevention. The press is often reporting broadly on such preprints, prior to peer review, and we have adapted to support that approach.

But it remains crucial to submit work that meets the highest scientific standards and delivers carefully thought-out conclusions. During this pandemic, we have seen the public and the press rely a lot on preprints as a source of information. Science and the public good do not benefit from publications that present shoddy science or poorly supported conclusions, so one has to be careful in evaluating and interpreting preprints.

What other challenges does this situation pose that we should know or be thinking about in the short and long term? {#sec1.8}
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**F.W.:** My lab members have used lockdown to write papers and analyze results---they have also been helping one another learn new data analytical skills. But as time goes on there is less to do, and we are keen to be back in the lab. I sense a renewed focus on the important research questions.

**D.S.:** Right now, our greatest challenge is logistical. We need to find creative ways to keep our science moving fast while limiting the number of scientists or support staff present in our research buildings at any given time.

But I think we also need to position ourselves now for the next possible outbreak. We need to put protocols in place that keep our workforce safe in this and the next epidemic. And we need to keep the scientific relationships we have established so we can quickly address the next emerging threats to public health.

I am concerned about the effects on our trainees, both in their productivity and in their job opportunities given the economic crisis. I am also worried about inequities in productivity in the coming years for those who may have disproportionate challenges related to childcare. There is the potential for exacerbation of gender and other diversity gaps that already exist, which would represent a step backward after years of sincere efforts to make progress in this important area.

Moving forward, what changes do you see staying in place for scientific research as a result of the pandemic response? {#sec1.9}
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**F.W.:** Zoom calls can work even better than face-to-face meetings because more people can participate. It is lovely to catch up with colleagues all over the world in the margins of these meetings. The serious business of evaluating grants, recommending the strategic direction of research institutions, and evaluating people for tenure has continued quite smoothly. Postdocs and Ph.D. students have been able to attend conferences for free or at much reduced cost---and that is great. But without face-to-face meetings it is hard to forge new relationships or get into unplanned conversations---so I hope that conferences and other gatherings resume in due course, even if at a lower intensity than previously.

**D.S.:** I'm hopeful that the cross-disciplinary collaborations that have been established will continue and scientists will continue to work with the greatest urgency and openness, as we are currently witnessing.

In addition, I'm hopeful that across the US and around the world, people will recognize how important it is to support scientific research, for both our physical and our economic health. The importance of innovation around health is not prominent in people's minds, and hopefully that will change.

What gives you hope? {#sec1.10}
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**G.Q.D.:** I am hopeful that this current crisis restores the public's faith and trust in the expertise of physicians and scientists and their essential role in recommending rational health care policy. I hope that people see that when their life, or that of a loved one, is at stake, they want decisions about health care delivery being shaped by the most informed and objective authorities and not left to the "gut" feelings of government leaders. I am inspired by the degree of solidarity and selfless collaboration that I've witnessed as the biomedical community confronts the global public health threat that the SARS-CoV-2 virus has wreaked upon humanity. Now is the time for scientists and clinicians everywhere to live up to their calling as servants in the public interest. Let's all work together to identify key vulnerabilities of SARS-CoV-2 that we can target, develop effective vaccines that will save lives, and glean insights into disease pathogenesis that will replace fear with confidence that we can control this pandemic with ingenuity and grit.

**F.W.:** Watching superb medical scientists like Tony Fauci (at the NIH) and Chris Whitty (the UK's Chief Medical officer) sharing the stage with politicians and being listened to at press briefings. I hope that science remains in the public consciousness and central to government thinking on health long after the pandemic passes.

**D.S.:** New technologies are enabling discovery at an incredible pace. For example, at Gladstone, Nevan Krogan and his team were able to create a map of all the interactions between SARS-CoV-2 proteins and human proteins in the span of just 2 weeks, highlighting many potential therapeutic targets.

The energy, commitment, and creativity of my colleagues give me great hope. I am confident we will innovate our way out of this problem.Deepak SrivastavaGladstone Institutes Fiona M. WattKing's College London George Q. DaleyHarvard Medical School
